Journal
PHARMACOLOGY & THERAPEUTICS
Volume 215, Issue -, Pages -Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.pharmthera.2020.107626
Keywords
Cirrhosis; Hepatic hemodynamic; Portal pressure; Hepatic stellate cells; Liver microcirculation
Categories
Funding
- Swiss National Science Foundation [SNF 320030_189252/1]
- Swiss Foundation against Liver Cancer
- Spanish Ministry of Science and Innovation - Instituto de Salud Carlos III [FIS PI17/00012]
- European Union FEDER Funds [AGAUR 2017-SGR-517]
- CERCA Program from the Generalitat de Catalunya
- Instituto de Salud Carlos III
- Stiftung fur Leberkrankheiten
- Asociacion Espanola Para el Estudio del Higado
- National Natural Science Foundation of China [81530019, 81900543]
Ask authors/readers for more resources
Portal hypertension (PH) is the most common non-neoplastic complication of chronic liver disease, determining clinical complications that lead to death or liver transplantation. PH results from increased resistance to portal blood flow through the cirrhotic liver, which is due to hepatic fibrosis and microcirculatory dysfunction. The present review focuses on the pathophysiology of fibrosis and PH, describes currently used treatments, and critically discusses potential therapeutic options. (C) 2020 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
